In COVID-19 clinical update #97, Daniel Griffin covers immunity after infection recognized by CDC, outcomes before and after Omicron, infectious viral load in Delta vs Omicron, PCR vs rapid antigen tests, booster interval shortened to 5 months, risk factors for severe outcomes in vaccinated, cross-reactive memory T cells, vaccine effectiveness vs MIS-C, and Rivaroxiban for thromboprophylaxis.

Subscribe (free): iTunes, Google Podcasts, RSS, email

Become a patron of TWiV!

Links for this episode

• Quarantine and isolation (CDC)
• Outcomes before and after Omicron (medRxiv)
• Infectious viral load in Delta vs Omicron infections (medRxiv)
• PCR vs rapid antigen test (medRxiv)
• Booster interval to 5 months (FDA)
• Cross-reactive memory T cells (Nat Comm)
• Risk factors for severe outcomes in vaccinated (MMWR)
• Vaccine effectiveness vs MIS-C (MMWR)
• Cross-reactive T cells to Omicron from vaccines (medRxiv)
• Rivaroxiban for thromboprophylaxis (Lancet)
• Letters read on TWiV 853
• Timestamps by Jolene. Thanks!

Intro music is by Ronald Jenkees Send your questions for Dr. Griffin to [email protected]